Survival Trends in Patients Under Age 65 Years With Mantle Cell Lymphoma, 1995–2016: A SEER-Based Analysis

Abstract

<b>Purpose:</b> The treatment paradigm for mantle cell lymphoma (MCL), a B-cell malignancy, has shifted considerably during the past decades. This study aimed to evaluate time trends in overall survival (OS) and disease-specific mortality (DSM) of younger (age ≤ 65 years) patients with MCL from 1995 to 2016. <b>Methods:</b> We used the Surveillance, Epidemiology, and End Results database. Year of diagnosis was divided into three eras: the chemotherapy-alone era (1995-2000), intensified-immunochemotherapy era (2001-2012), and targeted-therapy era (2013-2016). We used the Kaplan-Meier method, log-rank test, and subdistribution proportional hazard regression in the analysis. <b>Results:</b> A total 4,892 patients were identified. Median OS increased from 67 months in the chemotherapy-alone era to 107 months in the intensified-immunochemotherapy era (<i>P</i> < 0.001). The DSM rate decreased significantly from 1995 to 2016 (<i>P</i> < 0.001); the adjusted hazard ratios of MCL-specific death were 0.589 (<i>P</i> < 0.001) for the intensified-immunochemotherapy era and 0.459 (<i>P</i> < 0.001) for targeted-therapy era, as compared with the chemotherapy-alone era. Patients with advanced-stage MCL exhibited lowering risk of death across the three eras (<i>P</i> < 0.001). <b>Conclusions:</b> During 1995-2016, survival in younger patients with MCL increased significantly, especially those with advanced-stage disease, potentially reflecting the impact of advancement in treatment modalities on MCL outcome.